My question relates to the new payment system. Will clinical labs specializing in testing drugs of abuse, HCPCS codes G0480 through G0483, be subject to the initial collection and reporting periods outlined in the final PAMA rule?
According to the Centers for Medicare & Medicaid Services, the answer is yes. If the lab meets the definition of applicable laboratory, it would be subject to the reporting requirements. However, if no data is reported, CMS would use crosswalking or gapfilling methodologies to establish a price for the test.